|
|
|
|
| LEADER |
04711nma a2201321 u 4500 |
| 001 |
EB002040449 |
| 003 |
EBX01000000000000001184115 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a books978-3-0365-2458-0
|
| 020 |
|
|
|a 9783036524597
|
| 020 |
|
|
|a 9783036524580
|
| 100 |
1 |
|
|a Song, Im-Sook
|
| 245 |
0 |
0 |
|a Drug Metabolism/Transport and Pharmacokinetics
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2021
|
| 300 |
|
|
|a 1 electronic resource (232 p.)
|
| 653 |
|
|
|a kinetic analysis
|
| 653 |
|
|
|a hepatic CYP3A1(23)
|
| 653 |
|
|
|a stereoselectivity
|
| 653 |
|
|
|a protopanaxadiol (PPD)
|
| 653 |
|
|
|a HSG4112
|
| 653 |
|
|
|a renal clearance
|
| 653 |
|
|
|a celecoxib
|
| 653 |
|
|
|a drug dosing
|
| 653 |
|
|
|a healthy Korean subjects
|
| 653 |
|
|
|a BCRP
|
| 653 |
|
|
|a renal excretion
|
| 653 |
|
|
|a CYP3A4
|
| 653 |
|
|
|a drug-drug interaction
|
| 653 |
|
|
|a first-pass
|
| 653 |
|
|
|a UDP-glucuronosyltransferase
|
| 653 |
|
|
|a gentamicin
|
| 653 |
|
|
|a head-and-neck cancer
|
| 653 |
|
|
|a comparative pharmacokinetic study
|
| 653 |
|
|
|a creatinine clearance
|
| 653 |
|
|
|a influx transporter
|
| 653 |
|
|
|a tofacitinib
|
| 653 |
|
|
|a population pharmacokinetic
|
| 653 |
|
|
|a repaglinide
|
| 653 |
|
|
|a cisplatin
|
| 653 |
|
|
|a Caco-2
|
| 653 |
|
|
|a inhibitor
|
| 653 |
|
|
|a human hepatocytes
|
| 653 |
|
|
|a P-gp
|
| 653 |
|
|
|a intestinal metabolism
|
| 653 |
|
|
|a physiologically based pharmacokinetic model
|
| 653 |
|
|
|a compound K
|
| 653 |
|
|
|a drug transporter
|
| 653 |
|
|
|a notoginseng total saponins
|
| 653 |
|
|
|a anti-obesity agent
|
| 653 |
|
|
|a carboxylesterase
|
| 653 |
|
|
|a rats
|
| 653 |
|
|
|a metformin
|
| 653 |
|
|
|a sulfasalazine
|
| 653 |
|
|
|a modeling
|
| 653 |
|
|
|a automatization
|
| 653 |
|
|
|a kidney distribution
|
| 653 |
|
|
|a verapamil
|
| 653 |
|
|
|a tissue engineering
|
| 653 |
|
|
|a pharmacokinetics
|
| 653 |
|
|
|a transporter-enzyme interplay
|
| 653 |
|
|
|a UHPLC-MS/MS
|
| 653 |
|
|
|a EpiIntestinal
|
| 653 |
|
|
|a oral availability
|
| 653 |
|
|
|a quercetin
|
| 653 |
|
|
|a drug absorption
|
| 653 |
|
|
|a efflux transporter
|
| 653 |
|
|
|a DWP16001
|
| 653 |
|
|
|a sulfotransferase
|
| 653 |
|
|
|a catalposide
|
| 653 |
|
|
|a taxanes
|
| 653 |
|
|
|a Carthamus tinctorius extract
|
| 653 |
|
|
|a drug interaction
|
| 653 |
|
|
|a hepatic and intestinal first-pass effect
|
| 653 |
|
|
|a acute renal failure
|
| 653 |
|
|
|a cytochrome P450
|
| 653 |
|
|
|a HPLC
|
| 653 |
|
|
|a nonrenal clearance
|
| 653 |
|
|
|a diabetes
|
| 653 |
|
|
|a Manufacturing industries / bicssc
|
| 653 |
|
|
|a mertansine
|
| 653 |
|
|
|a inhibition mode
|
| 653 |
|
|
|a in vitro human metabolism
|
| 653 |
|
|
|a UDP-glucuronosyltransferases
|
| 653 |
|
|
|a real-time measurements
|
| 653 |
|
|
|a fluorescence
|
| 653 |
|
|
|a breast cancer resistance protein
|
| 653 |
|
|
|a organic cation transporter 2
|
| 653 |
|
|
|a prazosin
|
| 653 |
|
|
|a dose-dependent pharmacokinetics
|
| 653 |
|
|
|a cytochrome P450 enzymes
|
| 653 |
|
|
|a biliary excretion
|
| 653 |
|
|
|a metabolism
|
| 653 |
|
|
|a food-drug interactions
|
| 653 |
|
|
|a tiropramide
|
| 653 |
|
|
|a sodium-glucose cotransporter 2 (SGLT2) inhibitors
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a large volume direct injection
|
| 653 |
|
|
|a compatibility mechanism
|
| 700 |
1 |
|
|a Song, Im-Sook
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-0365-2458-0
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/4688
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/77070
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 380
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 620
|
| 520 |
|
|
|a This book serves to highlight the pharmacokinetics/drug-drug interactions and mechanistic understanding in relation to the drug-metabolizing enzymes and drug transporters.This book presents a series of drug metabolism and transport mechanisms that govern the pharmacokinetic features of therapeutic drugs as well as natural herbal medicines. It also covers the pharmacokinetic interactions caused by inhibiting or inducing the metabolic or transport activities under disease states or the coadministration of potential inhibitors. It also deals with microenvironmental pharmacokinetic profiles as well as population pharmacokinetics, which gives new insights regarding the pharmacokinetic features with regard to drug metabolism and transporters.
|